稳健医疗2025年三季报显示，前三季度公司主营收入78.97亿元，同比上升30.1%；归母净利润7.32亿 元，同比上升32.36%；扣非净利润6.79亿元，同比上升43.93%；其中2025年第三季度，公司单季度主营 收入26.01亿元，同比上升27.71%；单季度归母净利润2.4亿元，同比上升42.11%；单季度扣非净利润 2.18亿元，同比上升50.77%；负债率33.87%，投资收益3323.27万元，财务费用-203.6万元，毛利率 48.32%。稳健医疗（300888）主营业务：棉类制品的研发、生产、销售,覆盖医疗卫生、个人护理、家 庭护理、母婴护理、家纺服饰等。 证券之星消息，截至2026年2月11日收盘，稳健医疗(300888)报收于35.39元，下跌0.03%，换手率 0.33%，成交量1.92万手，成交额6808.36万元。 2月11日的资金流向数据方面，主力资金净流出1301.46万元，占总成交额19.12%，游资资金净流出 46.39万元，占总成交额0.68%，散户资金净流入1347.85万元，占总成交额19.8%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近 ...

报告内容概要： 藻酸盐敷料是以褐藻（如海带）提取的海藻酸钙纤维制成的医用敷料，属于第二类医疗器械，主要成分为藻酸盐。通过湿法纺丝工艺加工成无纺布或海绵形 态，部分产品添加银离子、氯化钙等功能性成分以增强止血、抗菌效果。该敷料接触伤口渗出液后形成凝胶，维持湿润环境并促进愈合，具有高吸湿性（可 吸收自身重量17-20倍液体），适用于褥疮、糖尿病足溃疡、烧伤等慢性渗出性伤口。藻酸盐敷料生产工艺包括湿法纺丝、水洗、牵伸及定型等工序，产品 形态涵盖片状、条状。其应用范围从手术止血敷料扩展至慢性创面护理，使用时需根据渗出量每1-3天更换，单次覆盖不超过7天。藻酸盐敷料按照规格主要 分为片状和条状，片状主要用于表浅伤口的治疗，而条状可以用于腔洞伤口、潜行和窦道等的治疗，由于其可以很容易地贴合伤口，因此可以用于各种形状 的伤口和各个解剖部位的伤口。数据显示，中国藻酸盐敷料行业市场规模从2017年的3.35亿元增长至2024年的34.21亿元，年复合增长率为39.37%。2025年 中国藻酸盐敷料行业市场规模约为37.83亿元。这一高速增长主要源于多重因素：人口老龄化加剧（2025年60岁以上人口占比达23%）直接推动慢性病患 ...

来自交易信息汇总：2月9日主力资金净流出869.52万元，游资资金亦呈净流出态势，散户资金则 净流入1547.5万元。 交易信息汇总资金流向 董秘最新回复 投资者： 公司的产品有进入沃尔玛、山姆会员店销售吗？ 董秘： 尊敬的投资者，您好！公司旗下消费品品牌"全棉时代"已进入沃尔玛、山姆会员店等零售体系 销售。作为重要渠道，公司积极拓展商超渠道，近两年渠道收入增速保持较好水平。公司将持续推进多 渠道布局，积极拓展国内外市场，以提升产品覆盖与品牌影响力。感谢您的关注与支持！ 当日关注点 截至2026年2月9日收盘，稳健医疗(300888)报收于35.71元，上涨0.0%，换手率0.57%，成交量3.34万 手，成交额1.19亿元。 2月9日主力资金净流出869.52万元；游资资金净流出677.98万元；散户资金净流入1547.5万元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - The company Steady Medical (300888) has shown significant growth in its financial performance for the first three quarters of 2025, with a notable increase in both revenue and net profit compared to the previous year [2]. Financial Performance - For the first three quarters of 2025, Steady Medical reported a total revenue of 7.897 billion yuan, representing a year-on-year increase of 30.1% [2]. - The net profit attributable to shareholders reached 732 million yuan, up 32.36% year-on-year [2]. - The company's net profit excluding non-recurring items was 679 million yuan, reflecting a 43.93% increase year-on-year [2]. - In the third quarter of 2025 alone, the company achieved a revenue of 2.601 billion yuan, which is a 27.71% increase compared to the same quarter last year [2]. - The net profit for the third quarter was 240 million yuan, marking a 42.11% year-on-year growth [2]. - The net profit excluding non-recurring items for the third quarter was 218 million yuan, showing a 50.77% increase year-on-year [2]. - The company's debt ratio stands at 33.87%, with investment income of 33.23 million yuan and financial expenses of -2.036 million yuan [2]. - The gross profit margin is reported at 48.32% [2]. Market Activity - As of February 9, 2026, Steady Medical's stock closed at 35.71 yuan, with a turnover rate of 0.57% and a trading volume of 33,400 hands, resulting in a transaction amount of 119 million yuan [1]. - On February 9, the net outflow of main funds was 8.6952 million yuan, accounting for 7.29% of the total transaction amount, while retail investors saw a net inflow of 15.475 million yuan, representing 12.97% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 10 institutions have provided ratings for Steady Medical, with 8 giving a "buy" rating and 2 giving a "hold" rating [2]. - The average target price set by institutions over the past 90 days is 5.451 billion yuan [2].

Group 1 - The core viewpoint of the article is that the company, Steady Medical, has successfully entered major retail channels such as Walmart and Sam's Club with its consumer brand "All Cotton Era" [1] - The company has maintained a good growth rate in channel revenue over the past two years, indicating effective expansion in the supermarket channel [1] - Steady Medical plans to continue its multi-channel strategy and actively expand both domestic and international markets to enhance product coverage and brand influence [1]

Core Viewpoint - The company, Steady Medical (300888.SZ), is expanding its consumer brand "All Cotton Era" into major retail channels such as Walmart and Sam's Club, indicating a strategic move to enhance market presence and brand influence [1] Group 1: Market Expansion - The company is actively expanding its supermarket channel, which has shown good revenue growth over the past two years [1] - The ongoing strategy includes a multi-channel layout to enhance product coverage and brand impact both domestically and internationally [1]

Core Viewpoint - The company, Steady Medical (300888.SZ), is expanding its consumer brand "All Cotton Era" into major retail channels such as Walmart and Sam's Club, indicating a strategic move to enhance market presence and brand influence [1] Group 1: Market Expansion - The company is actively expanding its supermarket channel, which has shown good revenue growth over the past two years [1] - The ongoing strategy includes a multi-channel layout to enhance product coverage and brand impact both domestically and internationally [1]

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary consumption sector, including Nike, Li Ning, Midea Group, JD Group, Haier Smart Home, Gree Electric, Anta Sports, and many others [1]. Core Insights - The report highlights that overseas consumer earnings releases have led to stock price volatility, with A/H shares anticipating a recovery in discretionary consumption in 2026 [1]. - The performance of various sectors is analyzed, with gaming, U.S. hotels, snacks, and retail showing positive trends, while luxury goods and overseas cosmetics are experiencing declines [4][12]. - The report notes that the gaming sector saw a strong increase in gross gaming revenue, with a year-on-year growth of 24%, exceeding market expectations [6][14]. Sector Performance Summary - **Gaming Sector**: Increased by 5.5%, driven by strong January gross gaming revenue growth and positive earnings from MGM China [6][14]. - **U.S. Hotels**: Also up by 5.5%, with Marriott and Hilton showing positive earnings forecasts [6][14]. - **Snacks**: Grew by 3.6%, with companies like Youyou Foods and Qiaqia Foods reporting significant growth expectations [6][14]. - **Retail Sector**: Increased by 3.5%, led by Walmart and Target, which exceeded market sales forecasts [8][14]. - **Domestic Sportswear**: Rose by 2.6%, with Li Ning benefiting from its partnership with the Chinese Olympic Committee [8][14]. - **Credit Card Sector**: Gained 2.3%, supported by strong earnings from Visa and Mastercard [8][14]. - **Domestic Cosmetics**: Increased by 2.1%, benefiting from overall strength in the beauty and skincare sector [8][14]. - **Luxury Goods**: Slightly up by 0.9%, influenced by a rebound in the U.S. market [8][14]. - **Overseas Cosmetics**: Decreased by 5.7%, with concerns over the sustainability of growth for Estée Lauder [9][15]. - **Pet Sector**: Down by 0.7%, with companies like Guai Bao Pet and Zhongchong Co. experiencing declines [8][14]. - **Gold and Jewelry**: Fell by 1.2%, affected by fluctuations in gold prices [8][14]. Valuation Analysis - The report indicates that the valuation of various sectors remains below their historical averages, with expected P/E ratios for 2025 showing significant discounts compared to the past five years [10].

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary consumption sector, including Nike, Li Ning, Midea Group, JD Group, Haier Smart Home, Gree Electric, Anta Sports, and many others [1]. Core Insights - The report highlights that overseas consumer earnings releases have led to stock price volatility, with A/H shares anticipating a recovery in discretionary consumption in 2026 [1]. - The performance of various sectors is analyzed, with gaming, U.S. hotels, snacks, and retail showing positive trends, while luxury goods and overseas cosmetics are experiencing declines [4][12]. - The report notes that the valuation of discretionary consumption sectors remains below the average of the past five years, indicating potential investment opportunities [10]. Sector Performance Summary - **Gaming Sector**: Increased by 5.5%, driven by strong growth in gross gaming revenue and positive earnings from major companies like MGM China [6][14]. - **U.S. Hotels**: Also up by 5.5%, with positive earnings forecasts from Marriott and Hilton [14]. - **Snacks Sector**: Rose by 3.6%, with companies like Youyou Foods and Qiaqia Foods showing strong sales growth [14]. - **Retail Sector**: Increased by 3.5%, led by Walmart and Target, which reported better-than-expected same-store sales [14]. - **Domestic Sportswear**: Grew by 2.6%, with Li Ning benefiting from its partnership with the Chinese Olympic Committee [14]. - **Credit Card Sector**: Up by 2.3%, supported by strong earnings from Visa and Mastercard [14]. - **Domestic Cosmetics**: Increased by 2.1%, benefiting from the overall strength in the beauty and skincare sector [14]. - **Luxury Goods**: Slightly up by 0.9%, influenced by a rebound in the U.S. market [14]. - **Overseas Sportswear**: Increased by 0.7%, with Nike announcing the opening of its first ACG store in Beijing [15]. - **Pet Sector**: Decreased by 0.7%, with companies like Guobao Pet and Zhongchong Co. facing declines [15]. - **Gold and Jewelry**: Down by 1.2%, affected by fluctuations in gold prices [15]. - **Overseas Cosmetics**: Fell by 5.7%, with Estée Lauder experiencing a significant drop [15].

Core Insights - The core viewpoint of the article highlights the rapid growth and increasing adoption of alginate dressings in the medical field due to their superior properties such as high absorbency, breathability, and antibacterial effects, making them a preferred choice for wound care, especially for complex wounds like burns and ulcers [1][12]. Industry Overview - The alginate dressing industry in China has seen its market size grow from 335 million yuan in 2017 to an estimated 3.421 billion yuan by 2024, with a compound annual growth rate (CAGR) of 39.37% [1][12]. - By 2025, the market size is projected to reach approximately 3.783 billion yuan [1][12]. - Key growth drivers include an aging population, increased health awareness, advancements in medical technology, and a growing preference for biodegradable materials [1][12]. Industry Development History - The alginate dressing industry in China began in the late 1980s, initially dominated by traditional gauze and cotton pads [7]. - The introduction of alginate dressings was facilitated by foreign companies in the early 1990s, but market penetration remained low due to high costs and limited clinical awareness [7]. - Domestic companies have since made significant technological advancements, overcoming key production challenges [7]. Industry Supply Chain - The supply chain for alginate dressings includes upstream raw materials such as alginate, silver ions, calcium chloride, and collagen [9]. - The midstream involves the production and manufacturing of alginate dressings, while the downstream encompasses sales channels including pharmaceutical companies, hospitals, pharmacies, and e-commerce platforms [9]. Competitive Landscape - The competitive landscape features both domestic and foreign companies, with foreign firms like ConvaTec and Smith & Nephew holding significant market shares in high-end products [12]. - Domestic companies such as Ma Ying Long, Weigao Group, and Steady Medical are actively pursuing technological innovation and market expansion [12]. Industry Trends - The industry is expected to see a shift towards smart and functional products, integrating technologies like pH monitoring and drug release systems to enhance treatment precision [16]. - Demand is anticipated to grow in chronic wound management and high-end care scenarios, driven by rising chronic disease rates and the expanding medical aesthetics market [17]. - Future products will focus on low allergenicity, biocompatibility, and ease of use to cater to sensitive skin and complex wound needs [19].